Context: Exogenous testosterone administration may affect blood clotting, polycythaemia, and may increase atherosclerosis, though any association with cardiovascular events is unclear. While the literature is inconclusive, some studies have suggested testosterone use may increase short-term risk of cardiovascular events and stroke, and injection testosterone may convey higher risks than other dosage forms.
| INTRODUC TION
There has been considerable debate and disagreement about the cardiovascular effects and safety of testosterone supplementation in the wake of its increasing use around the world, 1,2 particularly among men with unclear indications for its use. 1, 3 There have been concerns about testosterone's association with increased cardiovascular events, although there is substantial inconsistency in the literature; 4 many studies have suggested no increased cardiovascular risk associated with testosterone. [5] [6] [7] However, some studies have suggested increased risk of myocardial infarction, stroke and mortality in testosterone users [8] [9] [10] [11] -particularly short-term increases 12 in risk in older men 13 and those with pre-existing cardiovascular disease. 10 Testosterone treatment has been associated with various cardiovascular effects, such as increased coronary artery plaque volume, 14 increased red blood cell count 15 and the polycythaemia, 16, 17 and testosterone product labels carry warnings of venous thromboembolism. 18 While some regulatory agencies have warned of a potential for increased cardiovascular risk associated with testosterone use 19, 20 and taken steps to clarify/ narrow approved indications and limit expanding use of testosterone products, [20] [21] [22] conclusive agreement on the cardiovascular safety is still lacking. Concerns of unmeasured confounding and inappropriate comparator groups in prior nonrandomized studies, differences in the included populations in trials and nonrandomized studies and wide variation in testosterone use outside of clinical guidelines have all contributed to the current inconsistency and disagreement in the published studies and commentaries.
Testosterone is available in different dosage forms, including injections, transdermal patches and gels, and implants-each dosage form has unique pharmacodynamics, which may result in different safety profiles. Depending on the dose and dosing frequency, testosterone injections may result in immediate spikes in serum testosterone levels 23 compared with more subtle increases caused by transdermal applications. 24 These pharmacokinetic differences offer opportunities to study the impact of shorter-term exposure to higher levels of testosterone exposure. In a previous retrospective cohort study, we observed higher cardiovascular risks in injection testosterone users 11 relative to gel or patch users; these observed differences prompted further exploration of the potential risks associated with testosterone injections, particularly acute risks. These safety signals deserve further investigation to understand the risks associated with testosterone treatment.
The objective of this study was to estimate the short-term association of injection testosterone with acute cerebrovascular and cardiovascular events using large US data sources. Using a self-controlled case-crossover design, we evaluated the timing of acute events relative to testosterone injections.
| MATERIAL S AND ME THODS
We undertook a self-controlled case-crossover analysis of injection testosterone safety in 2 large US healthcare databases. 
| Outcome assessment
Case-crossover designs first identify men experiencing the outcome, and then evaluate exposures preceding the outcome to determine whether exposure was more likely to occur immediately before the outcome as compared to periods of time in the more distant past. We identified men experiencing myocardial infarction (MI), stroke or a composite of MI, stroke or unstable angina in the databases through diagnoses in hospitalization claims, with the day of hospital admittance as the index date. We identified MI as an inpatient claim with an ICD-9-CM diagnosis code of 410 or any subcode in the first or second position without any requirement for length of stay. 25, 26 Stroke was defined as an inpatient discharge ICD-9 codes 433.x1, 434. x1, 435.x, 436.x, 437.1x or 437.9x in any position. 27, 28 The composite was a combination of either MI or stroke, or unstable angina (discharge ICD-9 code 411.xx in the first or second position). 29 As the case-crossover is a case-only analysis, each outcome necessitated a separate cohort of men experiencing that outcome; a man could contribute to multiple outcome-specific analyses.
| Exposure assessment
Testosterone injections preceding the outcome were identified from both in-office procedure claims and pharmacy dispensing codes.
Included formulations included testosterone cypionate, enanthate, propionate and suspensions; testosterone undecanoate was not included, as it was not approved in the United States during the study period.
For sensitivity analyses, we considered all testosterone dosage forms as a class: testosterone gels and patches were identified with pharmacy dispensing claims; implants were identified from procedure claims. In both analyses, for all dosage forms, the stated service date of the procedure or pharmacy dispensing date was considered the day of exposure onset.
| Descriptive characteristics
To describe the clinical characteristics of the included men, we searched insurance claims occurring up to 1 year preceding the index outcome date to identify relevant diagnosis and procedure claims.
Each outcome-specific analysis is restricted to only those who experienced the current outcome of interest, so for the overall descriptive analysis, we used the composite outcome cohort which contains the other, outcome-specific cohorts. We identified symptoms and TA B L E 1 Characteristics of injection testosterone-using men in the year before experiencing one of the composites of outcomes of myocardial infarction, stroke or unstable angina, by data source explicit diagnoses of hypogonadism, cardiovascular conditions and recent cardiovascular events, other comorbidities, and preventive care and screening received (see Table 1 for complete list). These characteristics are for descriptive purposes only, and they are not included in the case-crossover analysis, which implicitly controls for within-person characteristics.
| Statistical analysis
We performed a case-crossover analysis to assess outcomes occurring immediately after receiving testosterone injections, as testosterone injections may result in acute spikes in serum testosterone levels. analysis. The 7 days prior to the admission date served as the focal window, during which receipt of testosterone was assessed. We defined 6 adjacent 7-day referent periods in each individual prior to the risk period to assess previous receipt of testosterone ( Figure 1 ). In the primary analysis, a 30-day gap separated the last referent window and the beginning of the focal window, but we varied the length from 14 to 90 days in sensitivity analyses to test the effects of different gaps between the focal and referent windows. We wanted gaps long enough to allow for the resolution of short-term effects of previous injections;
however, case-crossover designs may be influenced by overall increasing time trends in medication usage, where all later time periods may be more likely to be exposed simply due to increasing use, so we also wanted gaps short enough to not be influenced by long-term trends.
We estimated the association of testosterone receipt with each outcome separately using conditional logistic regression, estimating odds ratios (OR) and 95% confidence intervals (CI).
As a sensitivity analysis, we additionally performed another case-crossover analysis considering the receipt of any testosterone product (pharmacy dispensing, injection or implant) as an exposure event, allowing for switching between dosage forms in the focal and referent windows. We sought to evaluate whether acute cardiovascular outcomes were associated with the receipt of any testosterone or simply due to overall, increasing testosterone usage trends across the study period, rather than unique to testosterone injections.
Lastly, we performed an ad hoc sensitivity analysis restricting to only in-office administered injections; in the primary analysis, injections could be identified from both in-office procedure claims with exact administration dates, or pharmacy dispensing claims where the dispensing date is known, but the actual use by the patient is unknown.
| RE SULTS
We identified 284 218 eligible commercially insured men who experienced the composite outcome, and 91 348 in Medicare. Only those with discrepant testosterone exposure between the focal and referent windows prior to the event were retained for analysis, resulting in 1266 included commercially insured patients (mean age = 57.3, SD 7.7) and 208 in Medicare (mean age = 75.4, SD 6.9)
for our primary analysis of testosterone injections. Of all the injections received in the commercial insurance population, 85% were testosterone cypionate, 11% testosterone enanthate, 3% testosterone suspensions and 1% testosterone propionate; in Medicare, 85% were testosterone cypionate, 13% testosterone enanthate and other counts were too small to report, per Medicare privacy rules.
The prevalence of cardiovascular conditions, recent cardiovascular events and other comorbidities was high in these populations of testosterone users, and the characteristics of the injection testosterone users differed greatly by data source; the older, Medicare population had higher levels of most comorbidities (Table 1) . Additionally, the older, Medicare population had higher frequencies of recorded diagnoses of hypogonadism and serum testosterone tests, as well as more frequent diagnoses associated with hypogonadism, including fatigue, osteoporosis and sexual dysfunction.
In the younger, commercially insured population, the new receipt of testosterone injections was not associated with short-term increased risk of MI, stroke or the composite outcome ( Figure 2 , In the sensitivity analysis considering all testosterone products, we identified 2898 men in commercial-insured (mean age = 57.6, SD 7.5) and 334 in Medicare (mean age = 75.0, SD 7.1) experiencing an Any testosterone analysis in the commercial insurance population was similarly null as the injection analysis; OR = 1.01 (95% CI: 0.92, 1.11).
In sensitivity analyses when the gap between the risk and control periods was varied, the conclusions drawn from the resulting effect estimates were essentially unchanged across the different analyses (Table 3) . However, for some outcomes, the ORs were slightly elevated in the analysis using longer gaps.
In the commercial insurance, 33.4% of all injections received during the study windows were pharmacy-dispensed prescriptions, and the rest were administered in-office; in Medicare, 15.0% were pharmacydispensed. In a sensitivity analysis considering only in-office administered injections, the commercial insurance estimate for the composite outcome was similarly null to the primary analysis, OR = 1.03 (95% CI:
0.87, 1.23), and the Medicare result was elevated above the primary analysis, OR = 1.52 (95% CI: 1.08, 2.13).
| D ISCUSS I ON
In this large, multidatabase study of testosterone use, we observed acute increases in cardiovascular events associated with injections, although these increases were not consistent across all outcomes and databases. The case-crossover analysis suggested that receiving an injection is associated with increased risk of the composite outcome in the older, Medicare population. Within Medicare, the OR for the stroke and MI outcomes was consistent with the elevated composite estimate, though they are imprecise due to small numbers of cases. These increased associations were not observed in the younger, commercially insured population. Our work is consistent with some previous investigations of the cardiovascular safety of testosterone which have demonstrated relatively acute increases in cardiovascular risk, 10, 13 and stronger associations between testosterone use and cardiovascular events in the elderly 10,11,13 and those with pre-existing cardiovascular disease. indications for testosterone use are infrequently captured through diagnosis coding, and self-controlled designs allow us to avoid confounding by these unmeasured characteristics.
Using insurance claims has many advantages, mainly with respect to detailed medication and outcome information, yet they are limited in their lack of information on important personal characteristics for confounding control-to address the latter-we used a self-controlled design which does not require measuring these variables; however, the case-crossover design makes important assumptions about the timing of exposure effects, and violations of these assumptions may result in biased estimates. To test our assumptions about the timing, we performed sensitivity analyses varying the length of gaps in the case-crossover analysis; while the results were consistent for the composite outcome across all gap lengths, the small increases in OR estimates observed in some of the 60-and 90-day gap analyses may be due to the increasing prevalence of testosterone across the study period, 1 making events more likely to be in periods of testosterone use. To assess this potential bias, we used multiple referent windows within individuals, and multiple gap lengths between the focal and referent windows, which generally were consistent, although some outcome estimates were slightly elevated when using the longer gaps.. Additionally, the "all testosterone" sensitivity analysis resulted in null or attenuated estimates; although the Medicare composite OR remained somewhat elevated (OR = 1.26, 95% CI: 0.98, 1.63), the reduced or null results in these analyses do not suggest that the simple time trends of increasing testosterone use across the study period explain the entirety of the observed injection associations; furthermore, injection use was generally decreasing during the study period, further not explaining the observed injection associations.
Valid estimates require accurately identifying true exposure times;
injections and implants identified through in-office procedures are very reliable as the exact date of receipt is known, but we do not have information about whether or how pharmacy-dispensed prescriptions are actually used; we assigned the dispensing date as the exposure date, and we used 7-day focal and referent windows to allow for some variability TA B L E 2 Case-crossover analysis of testosterone injections and all testosterone receipt with acute cardiovascular and cerebrovascular events, 30- 
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